Arndt Vogel: ICI monotherapy is a not to missed option in HCC
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X:
“Off the press: Tislelizumab versus Sorafenib in 1st line treatment of HCC: Impact on Health-Related Quality of Life in RATIONALE-301 Study Liver Cancer. ICI monotherapy is a not to missed option in HCC, specifically for frail pts.”
Authors: Richard S. Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Ramil Abdrashitov, Yaxi Chen, Songzi Li, Andrew X. Zhu, Shukui Qin and Arndt Vogel.
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023